CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Regen BioPharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Regen BioPharma Inc
4700 Spring Street, Suite 304
Phone: (619) 722-5505p:619 722-5505 LA MESA, CA  91942  United States Ticker: RGBPRGBP
On 5/3/2024, the Securities and Exchange Commission (SEC) charged BF Borgers CPA PC and its owner, Benjamin F. Borgers, with significant violations of Public Company Accounting Oversight Board (PCAOB) standards across more than 1,500 SEC filings from January 2021 to June 2023. The charges included falsely representing compliance with PCAOB standards to clients, fabricating audit documentation, and inaccurately stating compliance in audit reports. According to the SEC's order, of 369 BF Borgers' clients whose public filings from January 2021 through June 2023 incorporated the firm's audits and reviews, at least 75 percent of the filings incorporated audits and reviews that did not comply with PCAOB standards. The financials in this report may include past audits and reviews conducted by BF Borgers CPA PC that are deemed not compliant with PCAOB standards.
This is a Subsidiary, click here for the Parent Company
Business Summary
Regen BioPharma, Inc. is a biotechnology company. The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space. The Company is also focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal products under development include HemaXellarate I, HemaXellerate II, dCellVax and DiffronC. HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20249/30/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary David R.Koos 63 3/23/2021 4/24/2013

Business Names
Business Name
RGBP
RGBPD

General Information
Number of Employees: 1 (As of 11/7/2023)
Outstanding Shares: 10,516,470 (As of 11/4/2024)
Shareholders: 454
Stock Exchange: OTC
Federal Tax Id: 455192997
Fax Number: (619) 330-2328


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024